<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" article-type="research-article"><?properties open_access?><?properties manuscript?><front><journal-meta><journal-id journal-id-type="nlm-journal-id">101256108</journal-id><journal-id journal-id-type="pubmed-jr-id">32579</journal-id><journal-id journal-id-type="nlm-ta">Int J Obes (Lond)</journal-id><journal-id journal-id-type="iso-abbrev">Int J Obes (Lond)</journal-id><journal-title-group><journal-title>International journal of obesity (2005)</journal-title></journal-title-group><issn pub-type="ppub">0307-0565</issn><issn pub-type="epub">1476-5497</issn></journal-meta><article-meta><article-id pub-id-type="pmid">28894292</article-id><article-id pub-id-type="pmc">5803459</article-id><article-id pub-id-type="doi">10.1038/ijo.2017.197</article-id><article-id pub-id-type="manuscript">NIHMS897816</article-id><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>Partitioning of Adipose Lipid Metabolism by Altered Expression and Function of PPAR Isoforms After Bariatric Surgery</article-title></title-group><contrib-group><contrib contrib-type="author"><name><surname>Jahansouz</surname><given-names>Cyrus</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Xu</surname><given-names>Hongliang</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref><xref rid="FN2" ref-type="author-notes">*</xref></contrib><contrib contrib-type="author"><name><surname>Hertzel</surname><given-names>Ann V.</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Kizy</surname><given-names>Scott S.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Steen</surname><given-names>Kaylee A.</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Foncea</surname><given-names>Rocio</given-names></name><degrees>PhD</degrees><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Serrot</surname><given-names>Federico J.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Kvalheim</surname><given-names>Nicholas</given-names></name><xref ref-type="aff" rid="A2">2</xref></contrib><contrib contrib-type="author"><name><surname>Luthra</surname><given-names>Girish</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A3">3</xref></contrib><contrib contrib-type="author"><name><surname>Ewing</surname><given-names>Kristin</given-names></name><degrees>RD LD</degrees><xref ref-type="aff" rid="A4">4</xref></contrib><contrib contrib-type="author"><name><surname>Leslie</surname><given-names>Daniel B.</given-names></name><degrees>MD</degrees><xref ref-type="aff" rid="A1">1</xref></contrib><contrib contrib-type="author"><name><surname>Ikramuddin</surname><given-names>Sayeed</given-names></name><degrees>MD</degrees><!--<email>Ikram001@umn.edu</email>--><xref ref-type="aff" rid="A1">1</xref><xref rid="FN1" ref-type="author-notes">&#x02020;</xref></contrib><contrib contrib-type="author"><name><surname>Bernlohr</surname><given-names>David A.</given-names></name><degrees>PhD</degrees><!--<email>Bernl001@umn.edu</email>--><xref ref-type="aff" rid="A2">2</xref><xref rid="FN1" ref-type="author-notes">&#x02020;</xref></contrib></contrib-group><aff id="A1">
<label>1</label>Department of Surgery, University of Minnesota. Minneapolis, MN 55455</aff><aff id="A2">
<label>2</label>Department of Biochemistry, Molecular Biology and Biophysics, University of Minnesota, MN, 55455</aff><aff id="A3">
<label>3</label>Park Nicollet Bariatric Surgery Center, St. Louis Park, MN</aff><aff id="A4">
<label>4</label>CentraCare Bariatric Center, St. Cloud, MN</aff><author-notes><corresp id="FN1"><label>&#x02020;</label>To whom correspondence should be addressed: Sayeed Ikramuddin (t: 612-624-1089; <email>Ikram001@umn.edu</email>) or David A. Bernlohr (t: 612-624-2712; <email>Bernl001@umn.edu</email>)</corresp><fn id="FN2" fn-type="equal"><label>*</label><p>These authors contributed equally to this work.</p></fn><fn id="FN3"><p>The corresponding authors have had full access to the data in the study and accept final responsibility for the decision to submit for publication.</p></fn></author-notes><pub-date pub-type="nihms-submitted"><day>7</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="epub"><day>14</day><month>8</month><year>2017</year></pub-date><pub-date pub-type="ppub"><month>2</month><year>2018</year></pub-date><pub-date pub-type="pmc-release"><day>14</day><month>2</month><year>2018</year></pub-date><volume>42</volume><issue>2</issue><fpage>139</fpage><lpage>146</lpage><!--elocation-id from pubmed: 10.1038/ijo.2017.197--><permissions><license><license-p>Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, subject always to the full Conditions of use:
<uri xlink:type="simple" xlink:href="http://www.nature.com/authors/editorial_policies/license.html#terms">http://www.nature.com/authors/editorial_policies/license.html#terms</uri></license-p></license></permissions><abstract><sec id="S1"><title>Background</title><p id="P1">Bariatric surgery remains the most effective treatment for reducing adiposity and eliminating type 2 diabetes, however the mechanism(s) responsible have remained elusive. Peroxisome proliferator activated receptors (PPAR) encompass a family of nuclear hormone receptors that upon activation exert control of lipid metabolism, glucose regulation, and inflammation. Their role in adipose tissue following bariatric surgery remains undefined.</p></sec><sec id="S2"><title>Materials and Methods</title><p id="P2">Subcutaneous adipose tissue biopsies and serum were obtained and evaluated from at time of surgery and on postoperative day 7 in patients randomized to Roux-en-Y gastric bypass (n=13) or matched caloric restriction (n=14), as well as patients undergoing vertical sleeve gastrectomy (n=33). Fat samples were evaluated for changes in gene expression, protein levels, &#x003b2;-oxidation, lipolysis, and cysteine oxidation.</p></sec><sec id="S3"><title>Results</title><p id="P3">Within 7 days, bariatric surgery acutely drives a change in the activity and expression of PPAR&#x003b3; and PPAR&#x003b4; in subcutaneous adipose tissue thereby attenuating lipid storage, increasing lipolysis and potentiating lipid oxidation. This unique metabolic alteration leads to changes in downstream PPAR&#x003b3;/&#x003b4; targets including decreased expression of FABP4 and SCD1 with increased expression of carnitine palmitoyl transferase 1 (CPT1) and uncoupling protein 2 (UCP2). Increased expression of UCP2 not only facilitated fatty acid oxidation (increased 15-fold following surgery) but also regulated the subcutaneous adipose tissue redoxome by attenuating protein cysteine oxidation and reducing oxidative stress. The expression of UCP1, a mitochondrial protein responsible for the regulation of fatty acid oxidation and thermogenesis in beige and brown fat, was unaltered following surgery.</p></sec><sec id="S4"><title>Conclusions</title><p id="P4">These results suggest that bariatric surgery initiates a novel metabolic shift in subcutaneous adipose tissue to oxidize fatty acids independently from the beiging process through regulation of PPAR isoforms. Further studies are required to understand the contribution of this shift in expression of PPAR isoforms as a contributor to weight loss following bariatric surgery.</p></sec></abstract></article-meta></front><body><sec sec-type="intro" id="S5"><title>Introduction</title><p id="P5">By the year 2040, global estimates of the prevalence of obesity-linked type 2 diabetes mellitus (T2DM) are approximately 640 million people worldwide<sup><xref rid="R1" ref-type="bibr">1</xref></sup>. The mainstay treatment remains weight loss achieved by lifestyle modifications and medications<sup><xref rid="R2" ref-type="bibr">2</xref></sup>. Unfortunately, these strategies have not shown durable success<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup>. As an endocrine organ, adipose tissue plays an important role in the pathogenesis of obesity and T2DM, and hyperplastic adipocytes secrete a variety of fatty acids and adipokines to achieve homeostasis<sup><xref rid="R5" ref-type="bibr">5</xref></sup>. The most effective treatment for obesity and T2DM is bariatric surgery<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R6" ref-type="bibr">6</xref>,<xref rid="R7" ref-type="bibr">7</xref></sup>. The two most common procedures are vertical sleeve gastrectomy (VSG) and Roux-en-Y gastric bypass (RYGB)<sup><xref rid="R8" ref-type="bibr">8</xref></sup>. For both procedures, by one-week post-surgery, insulin sensitivity is significantly improved with only minimal weight loss<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. However, the mechanism(s) responsible for such rapid metabolic changes after surgery has been incompletely characterized<sup><xref rid="R10" ref-type="bibr">10</xref></sup>.</p><p id="P6">The peroxisome proliferator-activated receptor &#x003b3; (PPAR&#x003b3;) nuclear receptor plays a major role in controlling adipocyte lipid storage and insulin sensitivity<sup><xref rid="R11" ref-type="bibr">11</xref>,<xref rid="R12" ref-type="bibr">12</xref></sup>. PPAR&#x003b4; is also abundantly expressed in adipose tissue and promotes lipid utilization by upregulating genes involved in fatty acid oxidation, such as carnitine palmitoyltransferase 1 (<italic>CPT1</italic>)<sup><xref rid="R13" ref-type="bibr">13</xref>,<xref rid="R14" ref-type="bibr">14</xref></sup>. Herein we report on a novel surgically-driven pathway resulting in increased adipose fatty acid &#x003b2;-oxidation derived from down-regulation of PPAR&#x003b3; and increased expression and activation of PPAR&#x003b4;. The switch in PPAR expression regulates several key target genes such as FABP4, SCD1, CPT1 and UCP2. Moreover, increased expression of uncoupling protein 2 (<italic>UCP2</italic>) mediates a reduction in adipose tissue oxidative stress and changes the tissue redoxome profile.</p></sec><sec sec-type="materials|methods" id="S6"><title>Materials and Methods</title><sec id="S7"><title>Study design</title><p id="P7">The University of Minnesota and St. Cloud Hospital Institutional Review Boards approved all investigations and informed consent was obtained from each participant. Thirty-three patients &#x0003e; 21 years of age and BMI &#x02265; 35.0 kg/m<sup>2</sup> undergoing VSG were recruited and informed consent was obtained. Abdominal subcutaneous adipose tissue (SAT) biopsies from 20 of the VSG patients were processed for tissue analysis. Based on a treatment effect of &#x02212;0.5 after VSG and 0.18 after hypocaloric restriction for total effect of 0.68, we estimated that 12 patients per group would allow us to detect at least a 40% difference of tissue protein level of FABP4 between groups with the power of 0.8 and alpha value of 0.05. The details of the study methods of the 27 patients recruited and randomized to RYGB (<italic>n</italic>=13; 3 males and 10 females) or diet (<italic>n</italic>=14; 4 males and 10 females)have been published<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. Briefly, inclusion criteria included men and women older than 21 years of age with a BMI &#x02265; 35.0 kg/m<sup>2</sup>, and meeting criteria by ADA standards for pre-diabetes or T2DM. We exclude patients with severe medical comorbidities, inability to under go surgery, patients with unanticipated surgical complications, and subjects on thiazolidinediones (TZD) as these are known to affect the PPAR pathways.</p></sec><sec id="S8"><title>Clinical data</title><p id="P8">Demographic data on sex, age, and T2DM were collected for obese patients at the time of surgery and seven days following bariatric surgery. Weight and height were measured immediately prior to surgery (preop) and during the postoperative visit. Body mass index (BMI) was calculated as weight (kg) divided by height (m<sup>2</sup>).</p></sec><sec id="S9"><title>Surgical Procedures</title><p id="P9">Details of the surgical procedures have been previously described<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. With regards to the RYGB, a 20&#x02013;30 mL vertically oriented gastric pouch was constructed using 3.5 mm staples. A 10&#x02013;12 mm gastrojejunostomy was created in an antecolic, antegastric fashion, with the Roux limb measuring approximately 150 cm from the gastrojejunostomy. For the laparoscopic VSG, a 4.8 mm stapler load was used to divide the greater curvature of the stomach 5 cm from the pylorus and remaining 3 cm from the <italic>angularis incisura</italic>. 3.5 mm stapler loads were fired thereafter progressing up to the angle of His to complete the VSG.</p></sec><sec id="S10"><title>Tissue sampling and blood collection</title><p id="P10">SAT samples and blood specimens were obtained from patients on the day of intervention and seven days post-intervention. Approximately 2&#x02013;3 g of fat was obtained from each subject and either immediately frozen with liquid nitrogen and stored at &#x02212;80&#x000b0;C or processed by collagenase digestion, or for measurements of &#x003b2;-oxidation and lipolysis.</p></sec><sec id="S11"><title>Assessment of DM medication score and insulin resistance</title><p id="P11">Fasting plasma glucose and plasma insulin levels were obtained at the time of initiation of intervention and seven days post-intervention. Homeostasis Model of Assessment for Insulin Resistance (HOMA-IR) was calculated according to the method described by Matthews <italic>et al</italic><sup><xref rid="R16" ref-type="bibr">16</xref></sup>. Hemoglobin A1c (HbA1c) was determined preoperatively on 20 patients (<xref ref-type="supplementary-material" rid="SD1">S. Table 1</xref>).</p></sec><sec id="S12"><title>&#x003b2;-oxidation measurement in subcutaneous adipose tissue explants</title><p id="P12">Pre- and post-surgery SAT biopsies were minced and incubated with KRH buffer supplemented with <sup>14</sup>C-palmitic acid for 1 h at 37&#x000b0;C. Minced tissue were transferred with medium into a 20 ml-glass reaction vial, which has a 1 mL tube containing 400 &#x003bc;L of 1 M NaOH. Perchloric acid was added to stop the reaction, and samples were incubated for 1 h shaking at 80 rpm. <sup>14</sup>CO<sub>2</sub> was trapped into the central tube and measured by liquid scintillation counting.</p></sec><sec id="S13"><title>Lipolysis measurement in human subcutaneous adipose tissue explants</title><p id="P13">0.3 g of adipose tissue was minced and incubated with 500 &#x003bc;l assay buffer at 37&#x000b0;C for 1 hour. The tissue mixture was centrifuged at 500 &#x000d7; g for 10 minutes and the liquid between the pellet and floating adipose tissue was moved to a new tube. Free fatty acids were measured using kits obtained from Wako Diagnostics (Mountain View, CA) and glycerol was measured using a Glycerol Colorimetric Assay Kit from Cayman Chemical Company (Ann Arbor, MI), each sample was measured in triplicates and presented as a composite mean with standard error of the mean.</p></sec><sec id="S14"><title>Collagenase Digestion</title><p id="P14">After fat was obtained, it was immediately minced and digested with type I collagenase in Krebs-Ringers-HEPES (KRH) buffer supplemented with 10 mg/ml bovine serum albumin (BSA). After incubation at 37<bold>&#x000b0;</bold>C for one hour, the mixture was filtered with a cell strainer (100-&#x003bc;m-pore-size nylon; Falcon) to remove undigested tissues. The stromal vascular fraction (SVF) was collected by centrifugation at 500 &#x000d7; g for 10 minutes and both fractions, the floating primary adipocyte and the SVF were washed, and TRIzol &#x000a9; (Invitrogen, Carlsbad, CA) reagent was used for RNA isolation.</p></sec><sec id="S15"><title>Real-time PCR</title><p id="P15">Total RNA was extracted from approximately 0.3 g of adipose tissue using TRIzol &#x000a9; (Invitrogen, Carlsbad, CA) according to the manufacturer&#x02019;s instructions. After DNase treatment, cDNA was synthesized using iScript cDNA synthesis kit (BioRad, Hercules, CA). Relative quantification of mRNA was performed by RT-PCR using iQ SYBR green Supermix and the MyiQ detection system (BioRad, Hercules, CA). Each sample was measured in duplicate. Human primers for target genes are listed in <xref ref-type="supplementary-material" rid="SD1">Supplemental Table 3</xref>. Gene expression data are expressed as arbitrary units normalized to the reference gene hTBP.</p></sec><sec id="S16"><title>Immunoblotting</title><p id="P16">Immunoblotting was performed as previously described<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer supplemented with protease inhibitors. Equal amounts of protein were separated by SDS-PAGE and transferred to polyvinylidene difluoride (PVDF) membrane. After a blocking step, membranes were incubated with primary antibody overnight at 4&#x000b0;C. Membranes were washed and incubated with secondary antibody conjugated to Li-Cor IRDye for 1 h and visualized using Odyssey infrared imaging (Li-Cor Biosciences, Lincoln, NE). The antibodies used were anti-PPAR&#x003b3; (Santa Cruz, Dallas, Texas, sc-7273), anti-FABP4 (laboratory stock), anti-CD36 (R&#x00026;D Systems, Minneapolis, MN, AF2519), anti-Perilipin1 (American Research Products, Waltham, MA, 03-651156), anti-sulfenic acid modified cysteine (Milipore, Darmstadt, Germany, ABS30) and anti-&#x003b2;-actin (Sigma-Aldrich, St. Louis, MO, A3854).</p></sec><sec id="S17"><title>Mitochondrial isolation</title><p id="P17">Mitochondrial isolation was carried out as previously described<sup><xref rid="R17" ref-type="bibr">17</xref></sup>. Adipose tissue was minced in ice-cold mitochondrial isolation buffer (20 mM Tris pH 7.4, 220 mM mannitol, 70 mM sucrose, 1 mM EDTA, 0.1 mM EGTA) and supplemented with protease inhibitors. The tissue was then further homogenized with 15 strokes of a Dounce homogenizer and centrifuged at 700 &#x000d7; g for 10 minutes at 4&#x000b0; C. Avoiding the lipid layer, the supernatant was transferred to a fresh tube and centrifuged at 10,000 &#x000d7; g for 15 min at 4&#x000b0; C.</p></sec><sec id="S18"><title>Dimedone labeling of sulfenic acids</title><p id="P18">Mitochondria pellets were solubilized using sonication in radioimmunoprecipitation assay (RIPA) buffer containing protease inhibitors, 1 mM dimedone, 10 mM iodoacetamide, 10mM N-ethylmaleimide, and 200 units/mL catalase to metabolize intracellular hydrogen peroxide. The lysates were incubated for 1 hr on ice followed by the addition of Laemmli protein sample buffer and the proteins were separated on an SDS-PAGE gel for cysteine oxidation (sulfenic acid) detection<sup><xref rid="R18" ref-type="bibr">18</xref></sup>.</p></sec><sec id="S19"><title>ELISA measurement of serum FABP4</title><p id="P19">Serum FABP4 was measured with human FABP4 Quantikine ELISA kit from R&#x00026;D systems (#DFBP40) according to the manufacturer&#x02019;s instructions. Each sample was measured in duplicate.</p></sec><sec id="S20"><title>Statistical analysis</title><p id="P20">The data are expressed as mean &#x000b1; standard error. Statistical analysis was performed using unpaired two-sided Student&#x02019;s t-test when comparing between groups and paired two-sided Student&#x02019;s t-test to compare pre- and post-surgical measures within groups. Unadjusted Pearson correlations were calculated to evaluate relations between HbA1c and target of interest, and changes in FABP4 and hormone of interest. Data with p-values less than 0.05 were considered statistically significant, unless otherwise stated.</p></sec></sec><sec sec-type="results" id="S21"><title>Results</title><sec id="S22"><title>Expression of <italic>PPAR&#x003b3;</italic> and downstream targets decrease after bariatric surgery</title><p id="P21">VSG was initially performed on 20 subjects (<xref ref-type="supplementary-material" rid="SD1">Supplemental Table 1</xref>). One-week post-VSG, subjects had minimal, although statistically significant weight loss and an improved HOMA-IR (<xref rid="F1" ref-type="fig">Fig. 1A,B</xref>). Patients who were prediabetic or diabetic had higher initial HOMA-IR levels (5.3 &#x000b1; 0.9) and exhibited a greater decrement in levels post-surgery (3.4 &#x000b1; 0.5; <italic>P</italic> = 0.02).</p><p id="P22">SAT<italic>PPAR&#x003b3;</italic> mRNA levels decreased significantly one-week after VSG, on average by 60% (<xref rid="F1" ref-type="fig">Fig. 1C</xref>),along with several well-established PPAR&#x003b3; targets including fatty acid binding protein 4 (<italic>FABP4)</italic>, phosphodiesterase 3B (<italic>PDE3B)</italic>, adipose triglyceride lipase (<italic>ATGL)</italic>, cluster of differentiation 36 (<italic>CD36)</italic>, stearoyl-CoA desaturase 1 (<italic>SCD1)</italic>, uncoupling protein 1 (<italic>UCP1</italic>) and perilipin 1 (<xref rid="F1" ref-type="fig">Fig. 1D</xref>). Assessment of PPAR&#x003b3; protein levels indicated a similar trend (<italic>P</italic> = 0.09), on average decreasing by nearly 60% (<xref rid="F1" ref-type="fig">Fig. 1E</xref>). Furthermore, protein levels of CD36 also decreased significantly whereas Perilipin 1 trended downward (<xref rid="F1" ref-type="fig">Fig. 1E</xref>).</p><p id="P23">To identify which cell population(s) was responsible for the decreased expression of <italic>PPAR&#x003b3;</italic> and its gene targets, we performed collagenase digestion of SAT to obtain a primary adipocyte fraction (ADIP) and SVF. mRNA levels of <italic>PPAR&#x003b3;</italic> and its downstream targets were consistently decreased in both fractions. One notable exception was <italic>PDE3B</italic> mRNA, although decreased in ADIP, was nearly tripled in SVF (<xref rid="F1" ref-type="fig">Fig. 1F,G</xref>).</p><p id="P24">In addition to VSG, RYGB is a commonly performed bariatric procedure that adds a malabsorptive component to the treatment<sup><xref rid="R19" ref-type="bibr">19</xref></sup>. We previously performed a study that randomized obese diabetic subjects to RYGB versus a hypocaloric matched diet<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. Weight loss after RYGB was similar to that observed following VSG (<xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). The RYGB group had a higher HbA1c and was on more anti-diabetic medications than the VSG cohort<sup><xref rid="R15" ref-type="bibr">15</xref></sup>. While there was no decrease in <italic>PPAR&#x003b3;</italic> gene expression in post-RYGB patients, several <italic>PPAR&#x003b3;</italic> gene targets including PDE3B, ATGL, SCD1, and UCP1 decreased significantly or trended towards reduced levels (<xref ref-type="supplementary-material" rid="SD1">Fig. S1C</xref>). Protein levels of PPAR&#x003b3; and its downstream targets, CD36 and Perilipin 1, decreased or trended downward after RYGB, similar to that seen post-VSG (<xref ref-type="supplementary-material" rid="SD1">Fig. S1D</xref>).</p><p id="P25">In an attempt to reconcile the differences in diabetic status among our patients undergoing VSG as compared to RYGB, we pooled all surgical patient data together and evaluated whether preoperative diabetic status, specifically HbA1c or HOMA-IR, was associated with acute post-surgical differences in <italic>PPAR&#x003b3;</italic> gene expression and that of its downstream targets. HbA1c strongly correlated with changes in mRNA levels of <italic>PPAR&#x003b3;</italic> (<xref ref-type="supplementary-material" rid="SD1">Fig. S2A</xref>). HbA1c also correlated with several downstream targets, specifically <italic>FABP4</italic>, <italic>PDE3B</italic>, and <italic>CD36</italic>, but not with <italic>ATGL</italic> or <italic>SCD1</italic> (<xref ref-type="supplementary-material" rid="SD1">Fig. S2B&#x02013;F</xref>). These findings suggest that acutely after surgery, patients with higher preoperative HbA1c have smaller changes in <italic>PPAR&#x003b3;</italic> and downstream targets. As such, both bariatric procedures result in decreased adipose PPAR&#x003b3; activity, an effect previously suggested to improve insulin sensitivity<sup><xref rid="R20" ref-type="bibr">20</xref>,<xref rid="R21" ref-type="bibr">21</xref></sup>.</p></sec><sec id="S23"><title>Expression of <italic>PPAR&#x003b4;</italic> and its targets increase after bariatric surgery</title><p id="P26">PPAR&#x003b4; activity supports lipid metabolism in adipose and muscle via regulation of genes involved in fatty acid uptake, &#x003b2;-oxidation, and energy uncoupling. After VSG and RYGB, the expression of <italic>PPAR&#x003b4;</italic> increased 2&#x02013;3 fold in SAT (<xref rid="F2" ref-type="fig">Fig. 2A</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S4A</xref>). Furthermore, several downstream targets of PPAR&#x003b4;, including <italic>CPT1</italic>, pyruvate dehydrogenase kinase 4 (<italic>PDK4</italic>), perilipin 2, and angiopoietin like 4 (<italic>ANGPLT4</italic>), increased significantly after VSG (<xref rid="F2" ref-type="fig">Fig. 2B&#x02013;E</xref>). After RYGB, <italic>CPT1</italic> increased while <italic>PDK4</italic> did not change (<xref ref-type="supplementary-material" rid="SD1">Fig. S4B,C</xref>). In contrast to <italic>PPAR&#x003b3;</italic>, changes in <italic>PPAR&#x003b4;</italic> and <italic>CPT1</italic> did not correlate with preoperative HbA1c (<xref ref-type="supplementary-material" rid="SD1">Fig. S2H,I</xref>). <italic>PPAR&#x003b1;</italic>, another participant in lipid metabolism, and its downstream target, <italic>CPT2</italic>, were unchanged after bariatric surgery or hypocaloric diet (<xref rid="F2" ref-type="fig">Fig. 2F,G</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S4D,E</xref>). Overall, bariatric surgery is associated with a dramatic change in the expression and activity PPAR&#x003b3; and PPAR&#x003b4; in SAT resulting in reduced gene expression of enzymes and proteins associated with lipid synthesis in favor of those linked to lipid oxidation.</p></sec><sec id="S24"><title>Caloric restriction does not regulate PPAR&#x003b3; or PPAR&#x003b4; activity</title><p id="P27">It has been demonstrated that plasma glucose and insulin levels decrease as early as one-week after bariatric surgery prior to substantial weight loss and independent of diet<sup><xref rid="R9" ref-type="bibr">9</xref></sup>. To assess whether the observed post-surgical effects on PPAR&#x003b3; or PPAR&#x003b4; were dependent upon caloric restriction, we performed our analysis on a calorically restricted group from our previous randomized controlled trial<sup><xref rid="R15" ref-type="bibr">15</xref></sup>.</p><p id="P28">Although acute weight loss after hypocaloric restriction was similar to that observed in the surgical cohorts (<xref ref-type="supplementary-material" rid="SD1">Fig. S3A</xref>), there was no change in subcutaneous adipose <italic>PPAR&#x003b3;</italic> mRNA levels (<xref ref-type="supplementary-material" rid="SD1">Fig. S3B</xref>). Evaluations of adipose expression of PPAR&#x003b3; targets following hypocaloric restriction revealed increases in <italic>PDE3B</italic> and <italic>FABP4</italic>, decreases in <italic>SCD1</italic>, and no change in <italic>UCP1</italic> (<xref ref-type="supplementary-material" rid="SD1">Fig. S3C</xref>). In contrast to the surgical groups, PPAR&#x003b3; protein levels increased five-fold after hypocaloric restriction, without changes to CD36 or Perilipin 1 (<xref ref-type="supplementary-material" rid="SD1">Fig. S3D</xref>). Similarly, neither expression of <italic>PPAR&#x003b4;</italic> nor its downstream targets changed after hypocaloric diet (<xref ref-type="supplementary-material" rid="SD1">Fig. S4A&#x02013;C</xref>). As such caloric restriction does not induce a similar change in the activity of PPAR&#x003b3; or PPAR&#x003b4; as does bariatric surgery.</p></sec><sec id="S25"><title>Adipose tissue &#x003b2;-oxidation and lipolysis increase following VSG</title><p id="P29">To explore the functional consequences of increased PPAR&#x003b4; activity, we measured &#x003b2;-oxidation in adipose tissue explants from six additional subjects undergoing VSG (<xref ref-type="supplementary-material" rid="SD1">S. Table 2</xref>) using <sup>14</sup>C-palmitate oxidation. Consistent with the upregulation of PPAR&#x003b4; activity and targets, &#x003b2;-oxidation was increased 15-fold following VSG (<xref rid="F3" ref-type="fig">Fig. 3A</xref>). One potential contributor of &#x003b2;-oxidation is increased fatty acid availability via increased lipolysis<sup><xref rid="R22" ref-type="bibr">22</xref></sup>. Indeed, previous reports have shown via hyperinsulinemic-euglycemic clamps that lipolysis is increased after bariatric surgery<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>. Similar to that shown by Gastaldelli et al. and Camastra et al. following RYGB, adipose tissue explants obtained from seven VSG subjects (<xref ref-type="supplementary-material" rid="SD1">S. Table 2</xref>) one week after VSG demonstrated a 2-fold increase in lipolysis (<xref rid="F3" ref-type="fig">Fig. 3B&#x02013;D</xref>)<sup><xref rid="R9" ref-type="bibr">9</xref>,<xref rid="R23" ref-type="bibr">23</xref></sup>.</p><p id="P30">These results suggest that increased lipid mobilization following VSG leads to increased fatty acid oxidation within WAT. This increase in lipid oxidation does not appear to be due to beiging or browning since <italic>UCP1</italic> was not upregulated after bariatric surgery and indeed, shows a strong trend towards being downregulated (<xref rid="F1" ref-type="fig">Fig. 1D</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S1C</xref>).</p></sec><sec id="S26"><title>Bariatric surgery downregulates FABP4 and upregulatesFABP5</title><p id="P31">Fatty acid binding proteins, notably FABP4 and FABP5, play critical roles in lipid metabolism and are PPAR&#x003b3; and PPAR&#x003b4; targets, respectively<sup><xref rid="R24" ref-type="bibr">24</xref></sup>. As shown in <xref rid="F4" ref-type="fig">Fig. 4A and B</xref>, adipose FABP4 protein decreased nearly 40% per patient post&#x02013;VSG. Although <italic>FABP4</italic> mRNA levels did not significantly change in the RYGB population, protein levels dropped by nearly 20% (<xref rid="F4" ref-type="fig">Fig. 4A,B</xref>). FABP4 protein levels did not change in the diet cohort. FABP4 has also been identified as a circulating adipokine that could contribute to systemic insulin resistance through actions on liver and pancreatic &#x003b2;-cells<sup><xref rid="R25" ref-type="bibr">25</xref>,<xref rid="R26" ref-type="bibr">26</xref></sup>. Therefore, we measured the serum levels of FABP4 in the three cohorts one-week after intervention. While serum levels of FABP4 did not change in either the VSG or RYGB cohorts, they were increased by about 30% in the diet cohort (<xref ref-type="supplementary-material" rid="SD1">Fig. S5</xref>). Protein levels of FABP5, another fatty acid carrier in adipose tissue and a PPAR&#x003b4; target, increased after both VSG and RYGB (<xref ref-type="supplementary-material" rid="SD1">Fig. S6A,B</xref>), but not in the diet group (<xref ref-type="supplementary-material" rid="SD1">Fig. S6C</xref>).</p><p id="P32">Thus, consistent with altered expression of PPAR isoforms, there is an acute switch in lipid carrier proteins after bariatric surgery that results in the downregulation of FABP4 and upregulation of FABP5 in SAT. While FABP4 expression decreases in adipose tissue, a compensatory upregulation of FABP5 was observed. Interestingly, FABP5 has been reported to deliver ligands to activate PPAR&#x003b4;, resulting in increased expression of genes involved in &#x003b2;-oxidation<sup><xref rid="R27" ref-type="bibr">27</xref></sup>.</p></sec><sec id="S27"><title>Bariatric surgery increases UCP2 levels and decreases cysteine oxidation in SAT</title><p id="P33">We have previously demonstrated that reduced inflammation resulting from decreased FABP4 expression is dependent upon the upregulation of UCP2<sup><xref rid="R17" ref-type="bibr">17</xref></sup> and UCP2 has also been identified as a downstream target of PPAR&#x003b4; in a number of different tissues<sup><xref rid="R28" ref-type="bibr">28</xref></sup>. As shown in <xref rid="F4" ref-type="fig">Fig. 4C</xref>, <italic>UCP2</italic> expression increased approximately 7-fold following VSG and 3-fold following RYGB, but did not change in the diet cohort. Furthermore, <italic>UCP2</italic> was upregulated in both ADIP and SVF in VSG (<xref rid="F4" ref-type="fig">Fig. 4D</xref>). The changes in gene expression of UCP2 following surgery correlated with preoperative HbA1c (<xref ref-type="supplementary-material" rid="SD1">Fig. S2G</xref>).UCP2 exerts its cellular function, in part, by reducing reactive oxygen species (ROS) which, if left unchecked, can alter a variety of cellular functions by oxidizing protein residues such as cysteines<sup><xref rid="R29" ref-type="bibr">29</xref></sup>. Consistent with the upregulation of <italic>UCP2</italic>, we observed reduced cysteine oxidation in adipose tissue following VSG (<xref rid="F5" ref-type="fig">Fig. 5A,B</xref>).</p></sec></sec><sec sec-type="discussion" id="S28"><title>Discussion</title><p id="P34">Bariatric surgery is the most efficacious treatment of two of the most burdensome diseases in healthcare today: obesity and T2DM<sup><xref rid="R3" ref-type="bibr">3</xref>,<xref rid="R4" ref-type="bibr">4</xref></sup>. Here we report a novel finding of altered expression of PPAR&#x003b3; and PPAR&#x003b4; occurring acutely in subcutaneous adipose tissue of human subjects after bariatric surgery, independent of caloric restriction. This alteration in the main regulators of adipose tissue metabolism has important implications in energy metabolism and insulin sensitivity given the active role of SAT. While visceral adipose tissue has been considered the primary metabolically active depot, evidence suggests that SAT is also critical to overall energy metabolism, even serving as the preferred storage depot in postprandial states<sup><xref rid="R30" ref-type="bibr">30</xref></sup>. Furthermore, in a comparison of multiple weight loss interventions including bariatric surgery, SAT loss was consistently observed to be greater than visceral adipose tissue loss, and visceral fat loss was linked to subcutaneous fat loss<sup><xref rid="R31" ref-type="bibr">31</xref></sup>.</p><p id="P35">PPAR&#x003b3; in particular is a major mediator of adipose tissue biology and increasing the activity of PPAR&#x003b3; via TZDs has traditionally been considered insulin sensitizing. Paradoxically, humans with a less active PPAR&#x003b3; (Pro12Ala), also have improved glucose homeostasis and are metabolically protected against T2DM<sup><xref rid="R32" ref-type="bibr">32</xref>,<xref rid="R33" ref-type="bibr">33</xref></sup>. Furthermore, given its adipogenic function, increasing PPAR&#x003b3; activity has the side effect of weight gain<sup><xref rid="R34" ref-type="bibr">34</xref></sup>. Based on our findings of reduced PPAR&#x003b3; activity following both RYGB and VSG surgeries, TZDs may be mechanistically counterproductive to the beneficial effects of bariatric surgery.</p><p id="P36">The decreased adipose <italic>PPAR&#x003b3;</italic> expression and activity post-surgery indicates an acute metabolic switch that favors the use of adipose tissue for energy dissipation rather than for energy storage. Supporting this concept, increased PPAR&#x003b4; activity favors lipid utilization via increased fatty acid oxidation and energy uncoupling<sup><xref rid="R13" ref-type="bibr">13</xref></sup>. Indeed, in several mouse models exhibiting increased lipolysis in WAT, there is a concurrent increase in white adipose tissue <italic>PPAR&#x003b4;</italic> and <italic>UCP2</italic> expression that drives fatty acid oxidation and thermogenesis<sup><xref rid="R35" ref-type="bibr">35</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref></sup>. Furthermore, these models do not exhibit elevated serum free fatty acids or hepatic/skeletal muscle fatty acid oxidation demonstrating the important role that adipocyte fatty acid oxidation can play in overall energy metabolism and adiposity<sup><xref rid="R35" ref-type="bibr">35</xref>&#x02013;<xref rid="R37" ref-type="bibr">37</xref></sup>. Consistent with this, we observed a 15-fold increase in WAT fatty acid oxidation, increased lipolysis, and decreased serum fatty acids post-surgery. Fatty acid oxidation in WAT has been underappreciated since most lipolysis-liberated fatty acids are re-esterified or released under normal physiological conditions<sup><xref rid="R18" ref-type="bibr">18</xref></sup>. Fasting has been demonstrated to increase fatty acid oxidation in adipocytes by 2-fold<sup><xref rid="R18" ref-type="bibr">18</xref></sup>. Considering the surplus of triglycerides stored in adipose tissue of obese patients, a slight increase of the oxidation pathway over time might influence whole body energy balance. Further studies are required to understand the contribution of the increase in PPAR&#x003b4; activity as a contributor to weight loss following bariatric surgery. Our study demonstrates a dramatic increase in adipose tissue FFA disposal through an oxidative pathway post-bariatric surgery, independently from SAT browning via <italic>UCP1</italic> expression. This not only sheds light on potential mechanisms of the surgery in adipose tissue, but also provides support for therapeutic targets for the medical management of diabetes. Indeed, a PPAR&#x003b4; agonist has shown promise in clinical trials with regards to lipid metabolism<sup><xref rid="R38" ref-type="bibr">38</xref></sup>. In fact, a study that randomized patients to a PPAR&#x003b4; agonist or placebo found improvements in metabolic syndrome in PPAR&#x003b4; recipients<sup><xref rid="R38" ref-type="bibr">38</xref></sup>. While this study focused on the effects of PPAR&#x003b4; agonism on skeletal muscle, our findings suggest that adipose tissue may play a role in this improvement as well. Further evaluation is needed to clarify the effect of PPAR&#x003b4; agonism in SAT.</p><p id="P37">Decreased levels of FABP4 have been associated with improved insulin sensitivity in both humans and mice<sup><xref rid="R39" ref-type="bibr">39</xref>&#x02013;<xref rid="R41" ref-type="bibr">41</xref></sup>. A polymorphism at the promoter region of FABP4, which leads to a decrease of about 60% in expression, has been associated with a decreased risk of type 2 diabetes and cardiovascular disease<sup><xref rid="R42" ref-type="bibr">42</xref></sup>. In this study, we observed an average reduction of 40% and 20% of FABP4 protein levels after VSG and RYGB, respectively, independent of caloric restriction. Interestingly, FABP4 expression has been shown to decrease WAT fatty acid oxidation<sup><xref rid="R43" ref-type="bibr">43</xref></sup>. Therefore, decreased FABP4 post-surgery is consistent with increased &#x003b2;-oxidation. The increased fatty acid oxidation could generate mitochondrial reactive oxygen species<sup><xref rid="R44" ref-type="bibr">44</xref></sup>. However, Xu et al. as well as Steen et al. previously identified an inverse relationship between FABP4 and UCP2<sup><xref rid="R17" ref-type="bibr">17</xref>,<xref rid="R45" ref-type="bibr">45</xref>,<xref rid="R46" ref-type="bibr">46</xref></sup>. Indeed, the expression of <italic>UCP2</italic>, a downstream target of PPAR&#x003b4;, was increased over 7-fold in WAT after bariatric surgery. Notably, a polymorphism in the promoter region of UCP2 that increases its expression has been linked to a reduced risk of obesity and diabetes in humans<sup><xref rid="R47" ref-type="bibr">47</xref>&#x02013;<xref rid="R49" ref-type="bibr">49</xref></sup>.This dramatic increase of <italic>UCP2</italic> would be predicted to reduce ROS levels. Supportive of this, mitochondrial protein cysteine oxidation was decreased after bariatric surgery. As such, bariatric surgery results in a decrease in oxidative stress in adipose tissue. Although the current study focused on early changes after bariatric surgery, there is evidence of persistence of this pathway longitudinally. Affonso et al. reported increased <italic>UCP2</italic> expression in SAT of patients 6 months following RYGB and correlated this change with increased resting metabolic rate<sup><xref rid="R50" ref-type="bibr">50</xref></sup>. Moreover, Sim&#x000f3;n et al. as well as Terra et al. found decreased serum FABP4 levels at 6 and 12 months following RYGB<sup><xref rid="R51" ref-type="bibr">51</xref>,<xref rid="R52" ref-type="bibr">52</xref></sup>. Surprisingly, Engl and colleagues observed no change in serum FABP4 levels despite 25 kg weight loss at one year after laparoscopic gastric band placement, a purely dietary restrictive bariatric procedure. These studies in conjunction with our observations support a reduction in FABP4 that may be uniquely associated with bariatric surgery and not necessarily with caloric restriction alone<sup><xref rid="R53" ref-type="bibr">53</xref></sup>. As such, the downregulation of FABP4 may potentially serve as a biomarker to predict longitudinal outcomes.</p><p id="P38">In summary, we have identified a novel alteration in the activity of PPAR&#x003b3; and PPAR&#x003b4; that leads to the downregulation of FABP4 and upregulation of UCP2 in subcutaneous adipose tissue after bariatric surgery. The altered expression of these molecular regulators leads to a metabolic shift in adipose tissue involving an increase of white adipose tissue lipolysis, lipid utilization through adipose fatty acid oxidation, and the control of ROS via UCP2 activity that in sum may contribute to the benefits of bariatric surgery.</p></sec><sec sec-type="supplementary-material" id="S29"><title>Supplementary Material</title><supplementary-material content-type="local-data" id="SD1"><label>1</label><caption><p id="P39"><bold>Supplemental Figure 1</bold>: Expression of <italic>PPAR&#x003b3;</italic> and downstream targets in subcutaneous adipose tissue of RYGB patients. <bold>(A)</bold> Body weight of patients pre- and 7 days post-RYGB (<italic>n</italic>=13); <bold>(B)</bold> Relative <italic>PPAR&#x003b3;</italic> mRNA levels in SAT pre- and post-RYGB; <bold>(C)</bold> Relative mRNA levels of <italic>FABP4, PDE3B, ATGL, CD36, SCD</italic>, and <italic>UCP1</italic> in SAT pre- and post-RYGB (<italic>n</italic>=12); <bold>(D)</bold> SAT protein levels of PPAR&#x003b3;, CD36, and Perilipin 1 measured by western blot in patients pre- and post-RYGB (<italic>n</italic>=6). * denotes p&#x0003c;0.05; ** denotes p&#x0003c;0.01.</p><p id="P40"><bold>Supplemental Figure 2</bold>: Preoperative HbA1c correlates with changes in adipose tissue expression of <italic>PPAR&#x003b3;</italic>, PPAR&#x003b3; targets, <italic>UCP2, PPAR&#x003b4; and CPT1</italic>.Regression analysis of preoperative HbA1c and change in mRNA expression 7 days post-bariatric surgery: <bold>(A)</bold><italic>PPAR&#x003b3;</italic>; <bold>(B)</bold><italic>FABP4</italic>; <bold>(C)</bold><italic>PDE3B</italic>; <bold>(D)</bold><italic>ATGL</italic>; <bold>(E)</bold>
<italic>CD36</italic>; <bold>(F)</bold><italic>SCD</italic>; (<bold>G</bold>) <italic>UCP2</italic>; <bold>(H)</bold><italic>PPAR&#x003b4;</italic>; <bold>(I)</bold>
<italic>CPT1</italic>.</p><p id="P41"><bold>Supplemental Figure 3</bold>: Expression of <italic>PPAR&#x003b3;</italic> and downstream targets in calorically restricted patients. <bold>(A)</bold> Body weight of patients pre- and 7 days post-caloric restriction (<italic>n</italic>=14); <bold>(B)</bold> Relative <italic>PPAR&#x003b3;</italic> mRNA levels in SAT pre- and 7 days post-caloric restriction; <bold>(C)</bold> mRNA levels of <italic>FABP4, PDE3B, ATGL, CD36, SCD</italic> and <italic>UCP1</italic> in SAT of patients pre- and 7 days post-caloric restriction; <bold>(D)</bold> Protein levels of PPAR&#x003b3;, CD36, and Perilipin 1 measured by western blot in adipose tissue of patients pre- and 7 days post-caloric restriction (<italic>n</italic>=5). * denotes p&#x0003c;0.05; ** denotes p&#x0003c;0.01.</p><p id="P42"><bold>Supplemental Figure 4</bold>: RYGB increases <italic>PPAR&#x003b4;</italic> and <italic>CPT1</italic> in subcutaneous adipose tissue independent of caloric restriction. Relative mRNA levels in SAT pre- and 7 days post-RYGB (n=12) and caloric restriction (n=12): <bold>(A)</bold><italic>PPAR&#x003b4;</italic>; <bold>(B)</bold><italic>CPT1</italic>; <bold>(C)</bold>
<italic>PDK4</italic>; <bold>(D)</bold><italic>PPAR&#x003b1;</italic>; <bold>(E)</bold><italic>CPT2</italic>. * denotes p&#x0003c;0.05.</p><p id="P43"><bold>Supplemental Figure 5</bold>: Serum FABP4 measured pre- and post-bariatric surgery and diet. FABP4 measured in serum pre- and post-VSG, RYGB and diet (VSG: <italic>n</italic>=12; RYGB: <italic>n</italic>=13; diet: <italic>n</italic>=14). * denotes p&#x0003c;0.05.</p><p id="P44"><bold>Supplemental Figure 6</bold>: The downregulation of FABP5 occurs in SAT of patients following bariatric surgery, but not after caloric restriction. SAT FABP5 protein levels as determined by western blot in patients pre- and post- <bold>(A)</bold> VSG (<italic>n</italic>=5); <bold>(B)</bold> RYGB (<italic>n</italic>=6); <bold>(C)</bold> caloric restriction (<italic>n</italic>=6). ** denotes p&#x0003c;0.01.</p></caption><media xlink:href="NIHMS897816-supplement-1.xlsx" orientation="portrait" xlink:type="simple" id="d36e1223" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD2"><label>2</label><media xlink:href="NIHMS897816-supplement-2.xlsx" orientation="portrait" xlink:type="simple" id="d36e1227" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD3"><label>3</label><media xlink:href="NIHMS897816-supplement-3.xlsx" orientation="portrait" xlink:type="simple" id="d36e1231" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD4"><label>4</label><media xlink:href="NIHMS897816-supplement-4.tif" orientation="portrait" xlink:type="simple" id="d36e1235" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD5"><label>5</label><media xlink:href="NIHMS897816-supplement-5.tif" orientation="portrait" xlink:type="simple" id="d36e1239" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD6"><label>6</label><media xlink:href="NIHMS897816-supplement-6.tif" orientation="portrait" xlink:type="simple" id="d36e1243" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD7"><label>7</label><media xlink:href="NIHMS897816-supplement-7.tif" orientation="portrait" xlink:type="simple" id="d36e1247" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD8"><label>8</label><media xlink:href="NIHMS897816-supplement-8.tif" orientation="portrait" xlink:type="simple" id="d36e1251" position="anchor"/></supplementary-material><supplementary-material content-type="local-data" id="SD9"><label>9</label><media xlink:href="NIHMS897816-supplement-9.tif" orientation="portrait" xlink:type="simple" id="d36e1255" position="anchor"/></supplementary-material></sec></body><back><ack id="S30"><p>We thank the members of the Bernlohr laboratory, the University of Minnesota Department of Surgery Division of Gastrointestinal and Bariatric Surgery, the University of Minnesota Bionet Department, and the CentraCare Bariatric Center (St. Cloud, MN) for their assistance during the preparation of this manuscript. This study was done using computing resources at the University of Minnesota Supercomputing Institute.</p><p><bold>Funding:</bold></p><p>This work was supported by the American Diabetes Association (ADA 7-11-ST-01), NIH DK053189 to DAB and the Minnesota Obesity Center (NIH P30DK050456).</p></ack><fn-group><fn fn-type="COI-statement" id="FN4"><p>The authors declare no competing financial interests to disclose.</p></fn><fn id="FN5" fn-type="con"><p><bold>Author Contributions:</bold></p><p>C.J., H.X., A.V.H., S. I. and D.A.B. performed all experiments and data interpretation, and conceived the study design. G.L, D.B.L, and S.I. performed all surgeries and participated in all facets of serum and tissue collection. K.E. conceived dietary plan and ensured subject compliance. N.K, F.J.S, S.K., A.X and C.J. collected and stored all specimens. N.K., F.J.S, S.K., and C.J. performed all qRT-PCR analysis. A.V.H. and H.X. performed adipose tissue fractionation, western blot, fatty acid oxidation, fatty acid and glycerol measurements. K.S. measured cysteine oxidation in SAT. R.F. and H.X measured sera FABP4. C.J., H.X., A.V.H., S.K., S.I. and D.A.B wrote the paper.</p></fn><fn id="FN6"><p><xref ref-type="supplementary-material" rid="SD1">Supplementary information</xref> is available at The <italic>International Journal of Obesity&#x02019;s</italic> website.</p></fn><fn id="FN7"><p>All authors have nothing to disclose.</p></fn></fn-group><ref-list><ref id="R1"><label>1</label><element-citation publication-type="web"><collab>International Diabetes Federation (IDF)</collab><source>IDF Diabetes Atlas</source><edition>7th</edition><comment><ext-link ext-link-type="uri" xlink:href="http://idf.org">idf.org</ext-link></comment><year>2015</year><pub-id pub-id-type="doi">10.1289/image.ehp.v119.i03</pub-id></element-citation></ref><ref id="R2"><label>2</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Statements</surname><given-names>P</given-names></name></person-group><article-title>Standards of medical care in diabetes - 2012</article-title><source>Diabetes Care</source><year>2012</year><volume>35</volume><pub-id pub-id-type="doi">10.2337/dc12-s011</pub-id></element-citation></ref><ref id="R3"><label>3</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ikramuddin</surname><given-names>S</given-names></name><name><surname>Korner</surname><given-names>J</given-names></name><name><surname>Lee</surname><given-names>W-J</given-names></name><name><surname>Connett</surname><given-names>JE</given-names></name><name><surname>Inabnet</surname><given-names>WB</given-names><suffix>III</suffix></name><name><surname>Billington</surname><given-names>CJ</given-names></name><etal/></person-group><article-title>Roux-en-Y Gastric Bypass vs Intensive Medical Management for the Control of Type 2 Diabetes, Hypertension, and Hyperlipidemia The Diabetes Surgery Study Randomized Clinical Trial</article-title><source>JAMA</source><year>2013</year><volume>309</volume><fpage>2240</fpage><lpage>2249</lpage><pub-id pub-id-type="pmid">23736733</pub-id></element-citation></ref><ref id="R4"><label>4</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schauer</surname><given-names>PR</given-names></name><name><surname>Bhatt</surname><given-names>DL</given-names></name><name><surname>Kirwan</surname><given-names>JP</given-names></name><name><surname>Wolski</surname><given-names>K</given-names></name><name><surname>Brethauer</surname><given-names>SA</given-names></name><name><surname>Navaneethan</surname><given-names>SD</given-names></name><etal/></person-group><article-title>Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 3-Year Outcomes</article-title><source>N Engl J Med</source><year>2014</year><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="R5"><label>5</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tilg</surname><given-names>H</given-names></name><name><surname>Moschen</surname><given-names>AR</given-names></name></person-group><article-title>Adipocytokines: mediators linking adipose tissue, inflammation and immunity</article-title><source>Nat Rev Immunol</source><year>2006</year><volume>6</volume><fpage>772</fpage><lpage>783</lpage><pub-id pub-id-type="pmid">16998510</pub-id></element-citation></ref><ref id="R6"><label>6</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chondronikola</surname><given-names>M</given-names></name><name><surname>Harris</surname><given-names>LLS</given-names></name><name><surname>Klein</surname><given-names>S</given-names></name></person-group><article-title>Bariatric surgery and type 2 diabetes: are there weight loss-independent therapeutic effects of upper gastrointestinal bypass?</article-title><source>J Intern Med</source><year>2016</year><volume>280</volume><fpage>476</fpage><lpage>486</lpage><pub-id pub-id-type="pmid">27739136</pub-id></element-citation></ref><ref id="R7"><label>7</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>Y</given-names></name><name><surname>Corsino</surname><given-names>L</given-names></name><name><surname>Shantavasinkul</surname><given-names>PC</given-names></name><name><surname>Grant</surname><given-names>J</given-names></name><name><surname>Portenier</surname><given-names>D</given-names></name><name><surname>Ding</surname><given-names>L</given-names></name><etal/></person-group><article-title>Gastric Bypass Surgery Leads to Long-term Remission or Improvement of Type 2 Diabetes and Significant Decrease of Microvascular and Macrovascular Complications</article-title><source>Ann Surg</source><year>2016</year><volume>263</volume><fpage>1138</fpage><lpage>42</lpage><pub-id pub-id-type="pmid">26599565</pub-id></element-citation></ref><ref id="R8"><label>8</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abraham</surname><given-names>A</given-names></name><name><surname>Ikramuddin</surname><given-names>S</given-names></name><name><surname>Jahansouz</surname><given-names>C</given-names></name><name><surname>Arafat</surname><given-names>F</given-names></name><name><surname>Hevelone</surname><given-names>N</given-names></name><name><surname>Leslie</surname><given-names>D</given-names></name></person-group><article-title>Trends in Bariatric Surgery: Procedure Selection, Revisional Surgeries, and Readmissions</article-title><source>Obes Surg</source><year>2016</year><volume>26</volume><fpage>1371</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">26715330</pub-id></element-citation></ref><ref id="R9"><label>9</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Iaconelli</surname><given-names>A</given-names></name><name><surname>Gaggini</surname><given-names>M</given-names></name><name><surname>Magnone</surname><given-names>MC</given-names></name><name><surname>Veneziani</surname><given-names>A</given-names></name><name><surname>Rubino</surname><given-names>F</given-names></name></person-group><article-title>Short-Term Effects of Laparoscopic Adjustable Gastric Banding Versus Roux-en-Y Gastric Bypass</article-title><source>Diabetes Care</source><year>2016</year><month>8</month><fpage>1</fpage><lpage>7</lpage></element-citation></ref><ref id="R10"><label>10</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tam</surname><given-names>C</given-names></name><name><surname>Berthoud</surname><given-names>H-R</given-names></name><name><surname>Bueter</surname><given-names>M</given-names></name><name><surname>Chakravarthy</surname><given-names>M</given-names></name><name><surname>Geliebter</surname><given-names>A</given-names></name><name><surname>Hajnal</surname><given-names>A</given-names></name><etal/></person-group><article-title>Could the mechanisms of bariatric surgery hold the key for novel therapies?</article-title><source>A report from the Pennington Scientific Symposium Obes Rev</source><year>2011</year><volume>12</volume><fpage>984</fpage><lpage>994</lpage><pub-id pub-id-type="pmid">21729236</pub-id></element-citation></ref><ref id="R11"><label>11</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fuentes</surname><given-names>E</given-names></name><name><surname>Guzm&#x000e1;n-jofre</surname><given-names>L</given-names></name><name><surname>Moore-carrasco</surname><given-names>R</given-names></name><name><surname>Palomo</surname><given-names>I</given-names></name></person-group><article-title>Role of PPARs in inflammatory processes associated with metabolic syndrome</article-title><source>Mol Med Rep</source><year>2013</year><volume>8</volume><fpage>1611</fpage><lpage>1616</lpage><pub-id pub-id-type="pmid">24100795</pub-id></element-citation></ref><ref id="R12"><label>12</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tontonoz</surname><given-names>P</given-names></name><name><surname>Hu</surname><given-names>E</given-names></name><name><surname>Graves</surname><given-names>RA</given-names></name><name><surname>Budavari</surname><given-names>AI</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>mPPAR&#x003b3;2: Tissue-specific regulator of an adipocyte enhancer</article-title><source>Genes Dev</source><year>1994</year><volume>8</volume><fpage>1224</fpage><lpage>1234</lpage><pub-id pub-id-type="pmid">7926726</pub-id></element-citation></ref><ref id="R13"><label>13</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>YX</given-names></name><name><surname>Lee</surname><given-names>CH</given-names></name><name><surname>Tiep</surname><given-names>S</given-names></name><name><surname>Yu</surname><given-names>RT</given-names></name><name><surname>Ham</surname><given-names>J</given-names></name><name><surname>Kang</surname><given-names>H</given-names></name><etal/></person-group><article-title>Peroxisome-proliferator-activated receptor delta activates fat metabolism to prevent obesity</article-title><source>Cell</source><year>2003</year><volume>113</volume><fpage>159</fpage><lpage>170</lpage><pub-id pub-id-type="pmid">12705865</pub-id></element-citation></ref><ref id="R14"><label>14</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wagner</surname><given-names>K</given-names></name><name><surname>Wagner</surname><given-names>N</given-names></name></person-group><article-title>Pharmacology &#x00026; Therapeutics Peroxisome proliferator-activated receptor beta/delta (PPAR &#x003b2;/&#x003b4;) acts as regulator of metabolism linked to multiple cellular functions</article-title><source>Pharmacol Ther</source><year>2010</year><volume>125</volume><fpage>423</fpage><lpage>435</lpage><pub-id pub-id-type="pmid">20026355</pub-id></element-citation></ref><ref id="R15"><label>15</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jahansouz</surname><given-names>C</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Hertzel</surname><given-names>AV</given-names></name><name><surname>Serrot</surname><given-names>FJ</given-names></name><name><surname>Kvalheim</surname><given-names>N</given-names></name><name><surname>Cole</surname><given-names>A</given-names></name><etal/></person-group><article-title>Bile Acids Increase Independently From Hypocaloric Restriction After Bariatric Surgery</article-title><source>Ann Surg</source><year>2016</year><volume>264</volume><fpage>1022</fpage><lpage>1028</lpage><pub-id pub-id-type="pmid">26655924</pub-id></element-citation></ref><ref id="R16"><label>16</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Matthews</surname><given-names>D</given-names></name><name><surname>Hosker</surname><given-names>J</given-names></name><name><surname>Rudenski</surname><given-names>A</given-names></name><name><surname>Naylor</surname><given-names>B</given-names></name><name><surname>Treacher</surname><given-names>D</given-names></name><name><surname>Turner</surname><given-names>R</given-names></name></person-group><article-title>Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man</article-title><source>Diabetologia</source><year>1985</year><volume>28</volume><fpage>412</fpage><lpage>419</lpage><pub-id pub-id-type="pmid">3899825</pub-id></element-citation></ref><ref id="R17"><label>17</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Hertzel</surname><given-names>AV</given-names></name><name><surname>Steen</surname><given-names>KA</given-names></name><name><surname>Wang</surname><given-names>Q</given-names></name><name><surname>Suttles</surname><given-names>J</given-names></name><name><surname>Bernlohr</surname><given-names>DA</given-names></name></person-group><article-title>Uncoupling Lipid Metabolism from Inflammation Through FABP-dependent Expression of UCP2</article-title><source>Mol Cell Biol</source><year>2015</year><volume>35</volume><comment>MCB.01122-14</comment></element-citation></ref><ref id="R18"><label>18</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>T</given-names></name><name><surname>Zang</surname><given-names>Y</given-names></name><name><surname>Ling</surname><given-names>W</given-names></name><name><surname>Corkey</surname><given-names>BE</given-names></name><name><surname>Guo</surname><given-names>W</given-names></name></person-group><article-title>Metabolic partitioning of endogenous fatty acid in adipocytes</article-title><source>Obes Res</source><year>2003</year><volume>11</volume><fpage>880</fpage><lpage>887</lpage><pub-id pub-id-type="pmid">12855758</pub-id></element-citation></ref><ref id="R19"><label>19</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Ward</surname><given-names>M</given-names></name><name><surname>Prachand</surname><given-names>V</given-names></name></person-group><article-title>Surgical treatment of obesity</article-title><source>Gastrointest Endosc</source><year>2009</year><volume>70</volume><fpage>985</fpage><lpage>990</lpage><pub-id pub-id-type="pmid">19879406</pub-id></element-citation></ref><ref id="R20"><label>20</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cock</surname><given-names>T-A</given-names></name><name><surname>Houten</surname><given-names>SM</given-names></name><name><surname>Auwerx</surname><given-names>J</given-names></name></person-group><article-title>Peroxisome proliferator-activated receptor-gamma: too much of a good thing causes harm</article-title><source>EMBO Rep</source><year>2004</year><volume>5</volume><fpage>142</fpage><lpage>7</lpage><pub-id pub-id-type="pmid">14755307</pub-id></element-citation></ref><ref id="R21"><label>21</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Miles</surname><given-names>PDG</given-names></name><name><surname>Barak</surname><given-names>Y</given-names></name><name><surname>He</surname><given-names>W</given-names></name><name><surname>Evans</surname><given-names>RM</given-names></name><name><surname>Olefsky</surname><given-names>JM</given-names></name></person-group><article-title>Improved insulin-sensitivity in mice heterozygous for PPAR-gamma deficiency</article-title><source>J Clin Invest</source><year>2000</year><volume>105</volume><fpage>287</fpage><lpage>292</lpage><pub-id pub-id-type="pmid">10675354</pub-id></element-citation></ref><ref id="R22"><label>22</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yehuda-shnaidman</surname><given-names>E</given-names></name><name><surname>Buehrer</surname><given-names>B</given-names></name><name><surname>Pi</surname><given-names>J</given-names></name><name><surname>Kumar</surname><given-names>N</given-names></name><name><surname>Collins</surname><given-names>S</given-names></name></person-group><article-title>Acute Stimulation of White Adipocyte Respiration by PKA-Induced Lipolysis</article-title><source>Diabetes</source><year>2010</year><volume>59</volume><fpage>2474</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">20682684</pub-id></element-citation></ref><ref id="R23"><label>23</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Camastra</surname><given-names>S</given-names></name><name><surname>Gastaldelli</surname><given-names>A</given-names></name><name><surname>Mari</surname><given-names>A</given-names></name><name><surname>Bonuccelli</surname><given-names>S</given-names></name></person-group><source>Early and longer term effects of gastric bypass surgery on tissue-specific insulin sensitivity and beta cell function in morbidly obese patients with and without type 2 diabetes</source><year>2011</year><fpage>2093</fpage><lpage>2102</lpage></element-citation></ref><ref id="R24"><label>24</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Bernlohr</surname><given-names>DA</given-names></name></person-group><article-title>Metabolic functions of FABPs&#x02014;mechanisms and therapeutic implications</article-title><source>Nat Rev Endocrinol</source><year>2015</year><volume>11</volume><fpage>592</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">26260145</pub-id></element-citation></ref><ref id="R25"><label>25</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Scheja</surname><given-names>L</given-names></name><name><surname>Makowski</surname><given-names>L</given-names></name><name><surname>Uysal</surname><given-names>KT</given-names></name><name><surname>Wiesbrock</surname><given-names>SM</given-names></name><name><surname>Shimshek</surname><given-names>DR</given-names></name><name><surname>Meyers</surname><given-names>DS</given-names></name><etal/></person-group><article-title>Altered insulin secretion associated with reduced lipolytic efficiency in aP2(&#x02212;/&#x02212;) mice</article-title><source>Diabetes</source><year>1999</year><volume>48</volume><fpage>1987</fpage><lpage>1994</lpage><pub-id pub-id-type="pmid">10512363</pub-id></element-citation></ref><ref id="R26"><label>26</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Sekiya</surname><given-names>M</given-names></name><name><surname>Ertunc</surname><given-names>ME</given-names></name><name><surname>Burak</surname><given-names>MF</given-names></name><name><surname>Mayers</surname><given-names>JR</given-names></name><name><surname>White</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adipocyte lipid chaperone aP2 Is a secreted adipokine regulating hepatic glucose production</article-title><source>Cell Metab</source><year>2013</year><volume>17</volume><fpage>768</fpage><lpage>778</lpage><pub-id pub-id-type="pmid">23663740</pub-id></element-citation></ref><ref id="R27"><label>27</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Armstrong</surname><given-names>EH</given-names></name><name><surname>Goswami</surname><given-names>D</given-names></name><name><surname>Griffin</surname><given-names>PR</given-names></name><name><surname>Noy</surname><given-names>N</given-names></name><name><surname>Ortlund</surname><given-names>EA</given-names></name></person-group><source>Structural basis for ligand regulation of the fatty acid-binding protein 5, peroxisome proliferator-activated receptor &#x003b2;/&#x003b4; (FABP5-PPAR&#x003b2;/&#x003b4;) signaling pathway</source><year>2014</year><volume>289</volume><fpage>14941</fpage><lpage>14954</lpage></element-citation></ref><ref id="R28"><label>28</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Toral</surname><given-names>M</given-names></name><name><surname>Romero</surname><given-names>M</given-names></name><name><surname>Jim&#x000e9;nez</surname><given-names>R</given-names></name><name><surname>Robles-vera</surname><given-names>I</given-names></name><name><surname>Tamargo</surname><given-names>J</given-names></name><name><surname>Carmen</surname><given-names>M</given-names></name><etal/></person-group><article-title>Role of UCP2 in the protective effects of PPAR beta/delta activation on lipopolysaccharide-induced endothelial dysfunction</article-title><source>Biochem Pharmacol</source><year>2016</year><fpage>110</fpage><lpage>111</lpage><fpage>25</fpage><lpage>36</lpage></element-citation></ref><ref id="R29"><label>29</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Krauss</surname><given-names>S</given-names></name><name><surname>Zhang</surname><given-names>CY</given-names></name><name><surname>Lowell</surname><given-names>BB</given-names></name></person-group><article-title>The mitochondrial uncoupling-protein homologues</article-title><source>Nat Rev Mol Cell Biol</source><year>2005</year><volume>6</volume><fpage>248</fpage><lpage>261</lpage><pub-id pub-id-type="pmid">15738989</pub-id></element-citation></ref><ref id="R30"><label>30</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Koutsari</surname><given-names>C</given-names></name><name><surname>Ali</surname><given-names>AH</given-names></name><name><surname>Mundi</surname><given-names>MS</given-names></name><name><surname>Jensen</surname><given-names>MD</given-names></name></person-group><article-title>Storage of circulating free fatty acid in adipose tissue of postabsorptive humans: Quantitative measures and implications for body fat distribution</article-title><source>Diabetes</source><year>2011</year><volume>60</volume><fpage>2032</fpage><lpage>2040</lpage><pub-id pub-id-type="pmid">21659500</pub-id></element-citation></ref><ref id="R31"><label>31</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Merlotti</surname><given-names>C</given-names></name><name><surname>Ceriani</surname><given-names>V</given-names></name><name><surname>Morabito</surname><given-names>A</given-names></name><name><surname>Pontiroli</surname><given-names>AE</given-names></name></person-group><article-title>Subcutaneous fat loss is greater than visceral fat loss with diet and exercise, weight-loss promoting drugs, and bariatric surgery. A critical review and meta-analysis</article-title><source>Int J Obes</source><year>2017</year><fpage>1</fpage><lpage>11</lpage></element-citation></ref><ref id="R32"><label>32</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Altshuler</surname><given-names>D</given-names></name><name><surname>Hirschhorn</surname><given-names>JN</given-names></name><name><surname>Klannemark</surname><given-names>M</given-names></name><name><surname>Lindgren</surname><given-names>CM</given-names></name><name><surname>Vohl</surname><given-names>MC</given-names></name><name><surname>Nemesh</surname><given-names>J</given-names></name><etal/></person-group><article-title>The common PPARgamma Pro12Ala polymorphism is associated with decreased risk of type 2 diabetes</article-title><source>Nat Genet</source><year>2000</year><volume>26</volume><fpage>76</fpage><lpage>80</lpage><pub-id pub-id-type="pmid">10973253</pub-id></element-citation></ref><ref id="R33"><label>33</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Memisoglu</surname><given-names>A</given-names></name><name><surname>Hu</surname><given-names>FB</given-names></name><name><surname>Hankinson</surname><given-names>SE</given-names></name><name><surname>Manson</surname><given-names>JE</given-names></name><name><surname>De Vivo</surname><given-names>I</given-names></name><name><surname>Willett</surname><given-names>WC</given-names></name><etal/></person-group><article-title>Interaction between a peroxisome proliferator-activated receptor gamma gene polymorphism and dietary fat intake in relation to body mass</article-title><source>Hum Mol Genet</source><year>2003</year><volume>12</volume><fpage>2923</fpage><lpage>2929</lpage><pub-id pub-id-type="pmid">14506127</pub-id></element-citation></ref><ref id="R34"><label>34</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fonseca</surname><given-names>V</given-names></name></person-group><article-title>Effect of thiazolidinediones on body weight in patients with diabetes mellitus</article-title><source>Am J Med</source><year>2003</year><volume>115</volume><fpage>42</fpage><lpage>48</lpage></element-citation></ref><ref id="R35"><label>35</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jaworski</surname><given-names>K</given-names></name><name><surname>Ahmadian</surname><given-names>M</given-names></name><name><surname>Duncan</surname><given-names>RE</given-names></name><name><surname>Sarkadi-nagy</surname><given-names>E</given-names></name><name><surname>Varady</surname><given-names>A</given-names></name><name><surname>Hellerstein</surname><given-names>MK</given-names></name><etal/></person-group><article-title>AdPLA ablation increases lipolysis and prevents obesity induced by high fat feeding or leptin deficiency</article-title><source>Nat Med</source><year>2009</year><volume>15</volume><fpage>159</fpage><lpage>168</lpage><pub-id pub-id-type="pmid">19136964</pub-id></element-citation></ref><ref id="R36"><label>36</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tansey</surname><given-names>JT</given-names></name><name><surname>Sztalryd</surname><given-names>C</given-names></name><name><surname>Roush</surname><given-names>DL</given-names></name><name><surname>Zee</surname><given-names>JV</given-names></name><name><surname>Gavrilova</surname><given-names>O</given-names></name><name><surname>Reitman</surname><given-names>ML</given-names></name><etal/></person-group><article-title>Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity</article-title><source>Proc Natl Acad Sci U S A</source><year>2001</year><volume>98</volume><fpage>6494</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">11371650</pub-id></element-citation></ref><ref id="R37"><label>37</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saha</surname><given-names>PK</given-names></name><name><surname>Kojima</surname><given-names>H</given-names></name><name><surname>Martinez-botas</surname><given-names>J</given-names></name><name><surname>Sunehag</surname><given-names>AL</given-names></name><name><surname>Chan</surname><given-names>L</given-names></name></person-group><source>Metabolic Adaptations in the Absence of Perilipin</source><year>2004</year><volume>279</volume><fpage>35150</fpage><lpage>35158</lpage></element-citation></ref><ref id="R38"><label>38</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Riserus</surname><given-names>U</given-names></name><name><surname>Sprecher</surname><given-names>D</given-names></name><name><surname>Johnson</surname><given-names>T</given-names></name><name><surname>Olson</surname><given-names>E</given-names></name><name><surname>Hirschberg</surname><given-names>S</given-names></name><name><surname>Liu</surname><given-names>A</given-names></name><etal/></person-group><article-title>Activation of peroxisome proliferator-activated receptor (PPAR)delta promotes reversal of multiple metabolic abnormalities, reduces oxidative stress, and increases fatty acid oxidation in moderately obese men 1142</article-title><source>Diabetes</source><year>2008</year><volume>57</volume><fpage>332</fpage><lpage>339</lpage><pub-id pub-id-type="pmid">18024853</pub-id></element-citation></ref><ref id="R39"><label>39</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hotamisligil</surname><given-names>GS</given-names></name><name><surname>Johnson</surname><given-names>RS</given-names></name><name><surname>Distel</surname><given-names>RJ</given-names></name><name><surname>Ellis</surname><given-names>R</given-names></name><name><surname>Papaioannou</surname><given-names>E</given-names></name><name><surname>Spiegelman</surname><given-names>BM</given-names></name></person-group><article-title>Uncoupling of obesity from insulin resistance through a targeted mutation in aP2, the adipocyte fatty acid binding protein</article-title><source>Science (80-)</source><year>1996</year><volume>274</volume><fpage>1377</fpage><lpage>1379</lpage></element-citation></ref><ref id="R40"><label>40</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kaess</surname><given-names>BM</given-names></name><name><surname>Enserro</surname><given-names>DM</given-names></name><name><surname>McManus</surname><given-names>DD</given-names></name><name><surname>Xanthakis</surname><given-names>V</given-names></name><name><surname>Chen</surname><given-names>MH</given-names></name><name><surname>Sullivan</surname><given-names>LM</given-names></name><etal/></person-group><article-title>Cardiometabolic correlates and heritability of fetuin-A, retinol-binding protein 4, and fatty-acid binding protein 4 in the framingham heart study</article-title><source>J Clin Endocrinol Metab</source><year>2012</year><volume>97</volume><pub-id pub-id-type="doi">10.1210/jc.2012-1458</pub-id></element-citation></ref><ref id="R41"><label>41</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cao</surname><given-names>H</given-names></name><name><surname>Gerhold</surname><given-names>K</given-names></name><name><surname>Mayers</surname><given-names>JR</given-names></name><name><surname>Wiest</surname><given-names>MM</given-names></name><name><surname>Steve</surname><given-names>M</given-names></name><name><surname>Hotamisligil</surname><given-names>GS</given-names></name></person-group><article-title>Identification of a lipokine, a lipid hormone linking adipose tissue to systemic metabolism</article-title><source>Cell</source><year>2009</year><volume>134</volume><fpage>933</fpage><lpage>944</lpage></element-citation></ref><ref id="R42"><label>42</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tuncman</surname><given-names>G</given-names></name><name><surname>Erbay</surname><given-names>E</given-names></name><name><surname>Hom</surname><given-names>X</given-names></name><name><surname>De Vivo</surname><given-names>I</given-names></name><name><surname>Campos</surname><given-names>H</given-names></name><name><surname>Rimm</surname><given-names>EB</given-names></name><etal/></person-group><article-title>A genetic variant at the fatty acid-binding protein aP2 locus reduces the risk for hypertriglyceridemia, type 2 diabetes, and cardiovascular disease</article-title><source>Proc Natl Acad Sci U S A</source><year>2006</year><volume>103</volume><fpage>6970</fpage><lpage>5</lpage><pub-id pub-id-type="pmid">16641093</pub-id></element-citation></ref><ref id="R43"><label>43</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gan</surname><given-names>L</given-names></name><name><surname>Liu</surname><given-names>Z</given-names></name><name><surname>Cao</surname><given-names>W</given-names></name><name><surname>Zhang</surname><given-names>Z</given-names></name><name><surname>Sun</surname><given-names>C</given-names></name></person-group><article-title>FABP4 reversed the regulation of leptin on mitochondrial fatty acid oxidation in mice adipocytes</article-title><source>Nat Publ Gr</source><fpage>1</fpage><lpage>12</lpage></element-citation></ref><ref id="R44"><label>44</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zorov</surname><given-names>DB</given-names></name><name><surname>Juhaszova</surname><given-names>M</given-names></name><name><surname>Sollott</surname><given-names>SJ</given-names></name></person-group><article-title>Mitochondrial reactive oxygen species (ros) and ros-induced ros release</article-title><source>Physiol Rev</source><year>2014</year><volume>94</volume><fpage>909</fpage><lpage>950</lpage><pub-id pub-id-type="pmid">24987008</pub-id></element-citation></ref><ref id="R45"><label>45</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Hertzel</surname><given-names>AV</given-names></name><name><surname>Steen</surname><given-names>KA</given-names></name><name><surname>Bernlohr</surname><given-names>DA</given-names></name></person-group><article-title>Loss of Fatty Acid Binding Protein 4/aP2 Reduces Macrophage Inflammation Through Activation of SIRT3</article-title><source>Mol Endocrinol</source><year>2016</year><volume>30</volume><fpage>325</fpage><lpage>334</lpage><pub-id pub-id-type="pmid">26789108</pub-id></element-citation></ref><ref id="R46"><label>46</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Steen</surname><given-names>KA</given-names></name><name><surname>Xu</surname><given-names>H</given-names></name><name><surname>Bernlohr</surname><given-names>DA</given-names></name></person-group><article-title>FABP4 / aP2 regulates macrophage redox signaling and inflammasome activation via control of UCP2</article-title><source>Mol Cell Biol</source><year>2016</year><volume>37</volume><pub-id pub-id-type="doi">10.1128/MCB.00282-16</pub-id></element-citation></ref><ref id="R47"><label>47</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname><given-names>X</given-names></name><name><surname>Wieczorek</surname><given-names>S</given-names></name><name><surname>Franke</surname><given-names>A</given-names></name><name><surname>Yin</surname><given-names>H</given-names></name><name><surname>Pierer</surname><given-names>M</given-names></name><name><surname>Sina</surname><given-names>C</given-names></name><etal/></person-group><article-title>Association of UCP2 -866 G/A polymorphism with chronic inflammatory diseases</article-title><source>Genes Immun</source><year>2009</year><volume>10</volume><fpage>601</fpage><lpage>605</lpage><pub-id pub-id-type="pmid">19387457</pub-id></element-citation></ref><ref id="R48"><label>48</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Esterbauer</surname><given-names>H</given-names></name><name><surname>Schneitler</surname><given-names>C</given-names></name><name><surname>Oberkofler</surname><given-names>H</given-names></name><name><surname>Ebenbichler</surname><given-names>C</given-names></name><name><surname>Paulweber</surname><given-names>B</given-names></name><name><surname>Sandhofer</surname><given-names>F</given-names></name><etal/></person-group><article-title>A common polymorphism in the promoter of UCP2 is associated with decreased risk of obesity in middle-aged humans</article-title><source>Nat Genet</source><year>2001</year><volume>28</volume><fpage>178</fpage><lpage>183</lpage><pub-id pub-id-type="pmid">11381268</pub-id></element-citation></ref><ref id="R49"><label>49</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Vogler</surname><given-names>S</given-names></name><name><surname>Goedde</surname><given-names>R</given-names></name><name><surname>Miterski</surname><given-names>B</given-names></name><name><surname>Gold</surname><given-names>R</given-names></name><name><surname>Kroner</surname><given-names>A</given-names></name><name><surname>Koczan</surname><given-names>D</given-names></name><etal/></person-group><article-title>Association of a common polymorphism in the promoter of UCP2 with susceptibility to multiple sclerosis</article-title><source>J Mol Med</source><year>2005</year><volume>83</volume><fpage>806</fpage><lpage>811</lpage><pub-id pub-id-type="pmid">16021520</pub-id></element-citation></ref><ref id="R50"><label>50</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>de Oliveira</surname><given-names>B</given-names></name><name><surname>de Souza Pinhel</surname><given-names>M</given-names></name><name><surname>Nicoletti</surname><given-names>C</given-names></name><name><surname>de Oliveira</surname><given-names>C</given-names></name><name><surname>Quinhoneiro</surname><given-names>D</given-names></name><name><surname>Noronha</surname><given-names>N</given-names></name><etal/></person-group><article-title>UCP2 and PLIN1 Expression Affects the Resting Metabolic Rate and Weight Loss on Obese Patients</article-title><source>Obes Surg</source><year>2017</year><volume>27</volume><fpage>343</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">27376365</pub-id></element-citation></ref><ref id="R51"><label>51</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sim&#x000f3;n</surname><given-names>I</given-names></name><name><surname>Escot&#x000e9;</surname><given-names>X</given-names></name><name><surname>Vilarrasa</surname><given-names>N</given-names></name><name><surname>G&#x000f3;mez</surname><given-names>J</given-names></name><name><surname>Fern&#x000e1;ndez-Real</surname><given-names>JM</given-names></name><name><surname>Meg&#x000ed;a</surname><given-names>A</given-names></name><etal/></person-group><article-title>Adipocyte fatty acid-binding protein as a determinant of insulin sensitivity in morbid-obese women</article-title><source>Obesity (Silver Spring)</source><year>2009</year><volume>17</volume><fpage>1124</fpage><lpage>1128</lpage><pub-id pub-id-type="pmid">19197257</pub-id></element-citation></ref><ref id="R52"><label>52</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Terra</surname><given-names>X</given-names></name><name><surname>Quintero</surname><given-names>Y</given-names></name><name><surname>Auguet</surname><given-names>T</given-names></name><name><surname>Porras</surname><given-names>JA</given-names></name><name><surname>Hernandez</surname><given-names>M</given-names></name><name><surname>Sabench</surname><given-names>F</given-names></name><etal/></person-group><article-title>FABP 4 is associated with inflammatory markers and metabolic syndrome in morbidly obese women</article-title><source>Eur J Endocrinol</source><year>2011</year><volume>164</volume><fpage>539</fpage><lpage>547</lpage><pub-id pub-id-type="pmid">21257725</pub-id></element-citation></ref><ref id="R53"><label>53</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Engl</surname><given-names>J</given-names></name><name><surname>Ciardi</surname><given-names>C</given-names></name><name><surname>Tatarczyk</surname><given-names>T</given-names></name><name><surname>Kaser</surname><given-names>S</given-names></name><name><surname>Laimer</surname><given-names>M</given-names></name><name><surname>Laimer</surname><given-names>E</given-names></name><etal/></person-group><article-title>A-FABP&#x02013;a biomarker associated with the metabolic syndrome and/or an indicator of weight change?</article-title><source>Obesity (Silver Spring)</source><year>2008</year><volume>16</volume><fpage>1838</fpage><lpage>1842</lpage><pub-id pub-id-type="pmid">18535557</pub-id></element-citation></ref></ref-list></back><floats-group><fig id="F1" orientation="portrait" position="float"><label>Figure 1</label><caption><p>VSG downregulates <italic>PPAR&#x003b3;</italic> and PPAR&#x003b3; target expression in adipose tissue. <bold>(A)</bold> Body weight of patients pre- and one-week post-VSG (<italic>n</italic>=20); <bold>(B)</bold> HOMA-IR of patients pre- and one-week post-VSG; <bold>(C)</bold> Relative <italic>PPAR&#x003b3;</italic> mRNA levels in SAT pre- and one-week post-VSG (<italic>n</italic>=12); <bold>(D)</bold> Relative mRNA levels of <italic>FABP4</italic> (fatty acid binding protein 4), <italic>PDE3B</italic> (phosphodiesterase 3B), <italic>ATGL</italic> (adipose triglyceride lipase), <italic>CD36</italic> (cluster of differentiation 36), <italic>SCD</italic> (stearoyl-CoA desaturase 1), <italic>UCP1</italic> (uncoupling protein 1) in SAT pre- and one-week post-VSG (<italic>n</italic>=12); <bold>(E)</bold> Protein levels of PPAR&#x003b3;, CD36, and Perilipin 1 measured by western blot in adipose tissue of patients pre- and one-week post-VSG (<italic>n</italic>=4); <bold>(F)</bold> mRNA levels of <italic>PPAR&#x003b3;, FABP4, PDE3B, CD36</italic>, and <italic>SCD</italic> in the primary adipocyte fraction of SAT of patients pre- and one-week post-VSG (<italic>n</italic>=8); <bold>(G)</bold> mRNA levels of <italic>PPAR&#x003b3;, FABP4, PDE3B, CD36</italic>, and <italic>SCD1</italic> in stromal vascular fraction of SAT of patients pre- and one-week post-VSG (<italic>n</italic>=8). * denotes p&#x0003c;0.05; ** denotes p&#x0003c;0.01.</p></caption><graphic xlink:href="nihms897816f1"/></fig><fig id="F2" orientation="portrait" position="float"><label>Figure 2</label><caption><p>VSG upregulates <italic>PPAR&#x003b4;</italic> and PPAR&#x003b4; target expression in adipose tissue. Relative mRNA levels in SAT of subjects pre- and one week post-VSG (<italic>n</italic>=12) of <bold>(A)</bold>
<italic>PPAR&#x003b4;</italic>; <bold>(B)</bold>
<italic>CPT1</italic>; <bold>(C)</bold>
<italic>PDK4</italic>; <bold>(D)</bold>
<italic>Perilipin2</italic>; <bold>(E)</bold>
<italic>ANGPLT4</italic>; <bold>(F)</bold>
<italic>PPAR&#x003b1;</italic>; <bold>(G)</bold>
<italic>CPT2</italic>. * denotes p&#x0003c;0.05; ** denotes p&#x0003c;0.01.</p></caption><graphic xlink:href="nihms897816f2"/></fig><fig id="F3" orientation="portrait" position="float"><label>Figure 3</label><caption><p>VSG increases adipose tissue fatty acid oxidation and lipolysis. <bold>(A)</bold> &#x003b2;-oxidation measured in SAT pre- and post-VSG (<italic>n</italic>=6); <bold>(B)</bold> Secreted fatty acids measured in SAT pre- and post-VSG (<italic>n</italic>=7); <bold>(C)</bold> Secreted glycerol measured in SAT pre- and post-VSG (<italic>n</italic>=7); <bold>(D)</bold> Ratio of secreted fatty acids to glycerol from SAT pre- and post-VSG (<italic>n</italic>=7). ** denotes p&#x0003c;0.01.</p></caption><graphic xlink:href="nihms897816f3"/></fig><fig id="F4" orientation="portrait" position="float"><label>Figure 4</label><caption><p>The downregulation of FABP4 and upregulation of <italic>UCP2</italic> occurs in SAT of patients following bariatric surgery, but not after caloric restriction. <bold>(A</bold>&#x02013;<bold>B)</bold> SAT FABP4 protein levels as determined by western blot in patients pre- and post-VSG (<italic>n</italic>=6), RYGB (<italic>n</italic>=9), and caloric restriction (<italic>n</italic>=10). <bold>(C)</bold> SAT expression of <italic>UCP2</italic> mRNA in patients pre- and post-VSG (<italic>n</italic>=12), RYGB (<italic>n</italic>=13), and caloric restriction (<italic>n</italic>=14), as determined by qRT-PCR; (<bold>D</bold>) mRNA levels of <italic>UCP2</italic> in the primary adipocyte fraction (ADIP) and stromal vascular fraction (SVF) in SAT of patients pre- and 7 days post-VSG (<italic>n</italic>=8). * denotes p&#x0003c;0.05; ** denotes p&#x0003c;0.01.</p></caption><graphic xlink:href="nihms897816f4"/></fig><fig id="F5" orientation="portrait" position="float"><label>Figure 5</label><caption><p>Cysteine oxidation in SAT was decreased 7 days following VSG; (<bold>A</bold>) SAT cysteine oxidation levels in patients pre- and post-VSG (<italic>n</italic>=5); (<bold>B</bold>) Quantification of cysteine oxidation levels in SAT of patients pre- and post-VSG. Total intensity of cysteine oxidation was normalized to total protein for each sample using Ponceau S staining solution. * denotes p&#x0003c;0.05.</p></caption><graphic xlink:href="nihms897816f5"/></fig></floats-group></article>